Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of BAX 888 in Male Adults With Severe Hemophilia A
NCT03370172 · View on ClinicalTrials.gov ↗
Study Summary
The main aim of this study is to check if there are side effects from BAX 888 and to determine the dose of BAX 888 for treating severe hemophilia A in male adults. Participants will receive one infusion with BAX 888 at the hemophilia treatment center. During the study, participants will visit their study clinic multiple times.
Conditions Studied
Interventions
- DRUG BAX 888
Study Locations (20)
California
- Orthopaedic Hospital DBA Orthopaedic Hemophilia Treatment Center — Los Angeles
- UC Davis Medical Center — Sacramento
Other
- AKH - Medizinische Universität Wien — Vienna
- Vivantes Klinikum im Friedrichshain — Berlin
Arizona
- Phoenix Childrens Hospital — Phoenix
Colorado
- University of Colorado Hemophilia & Thrombosis Center — Aurora
New York
- Mount Sinai Medical Center — New York
Ohio
- Cincinnati Children's Hospital Medical Center — Cincinnati
South Carolina
- Medical University of South Carolina (MUSC) — Charleston
Texas
- Gulf States Hemophilia and Thrombophilia Center — Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2018-02-27 |
| Est. Completion | 2024-07-09 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03370172
The ClinicalTrials.gov registry entry for NCT03370172 describes a study currently listed as completed. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxalta now part of Shire, which has 12 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Hemophilia A appearing as the primary indexed condition, and to 1 intervention — of which BAX 888 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03370172 reports 20 study locations spanning 18 distinct geographic areas — top geographies include California, Other, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03370172 about?
NCT03370172 is a clinical study titled "A Study of BAX 888 in Male Adults With Severe Hemophilia A". The main aim of this study is to check if there are side effects from BAX 888 and to determine the dose of BAX 888 for treating severe hemophilia A in male adults. Participants will receive one infusion with BAX 888 at the hemophilia treatment center. During the study, participants will visit their...
What is the current status of trial NCT03370172?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2018-02-27. Estimated completion is 2024-07-09.
What conditions does trial NCT03370172 study?
This clinical trial studies the following conditions: Hemophilia A. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03370172?
The interventions under investigation include: BAX 888 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03370172?
This trial is sponsored by Baxalta now part of Shire, which has 12 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03370172 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.